Scientists have found that a gene that controls brain growth and development is heavily involved in promoting the most common form of kidney cancer, a finding that could lead to new strategy to treat the disease.
The study by researchers from Mayo Clinic in Florida shows that the gene NPTX2, plays an essential role in clear cell renal cell carcinoma, which is resistant to common chemotherapy and has a five-year overall survival rate of less than 10 per cent in patients with metastatic disease.
- Varun Gandhi Under Attack Over Defence Deals: Here’s How
- This Diwali, Let Blind Students Brighten Up your Homes With Candles & Diyas
- CBI Files Supplementary Chargesheet In Sheena Bora Murder Case
- Soha Ali Khan And Vir Das Starrer 31st October Audience Reaction
- Sahara Chief Subrata Roy’s Parole Extended Till November 28
- Simple Tips To Secure Your Debit Card From Fraudsters
- New Zealand & India Team Being Welcomed In Chandigarh
- Mumbai Call Centre Scam: All You Need To Know
- Jammu Kashmir Chief Minister Mehbooba Mufti Appeals To Police: Here’s What She Said
- Shocker From Ahmedabad: Find Out What Happened
- Bigg Boss 10 Day 3 Review: Celebs Fail To Do Well in First Task
- Airtel Offers 10GB Data At Rs 259 For New 4G Smartphone Users
- Aamir Khan Starrer Dangal’s Trailer Launched: First Impressions
- TMC Supporters Attack BJP Leader Babul Supriyo
- Sri Lankan Navy Apprehends 20 Indian Fishermen
The study not only shows that NPTX2 is active in kidney cancer, but is the first to reveal that the gene is over-expressed in any human cancer. The researchers are now looking whether NPTX2 may act in other cancers.
“We found that a gene known to play a role in the healthy brain is also the No 1 gene associated with this most lethal of all urological cancers,” said the study’s senior investigator and molecular biologist John A Copland.
“We also have very promising ideas about how to attack the NPTX2 protein – which may provide a much-needed new strategy to treat this kidney cancer,” said Copland.
Because the NPTX2 gene is not expressed in normal kidney tissue, a drug designed to target its protein would provide a highly focused treatment, Copland said. The team is working on several different approaches to an NPTX2 inhibitor.
Lead author Christina von Roemeling, a graduate student at Mayo Clinic, used genomic profiling of nearly 100 kidney cancer patient samples to identify genes that were either over-expressed or under-expressed as compared to patient matched normal kidney tissue samples.
Von Roemeling and the research team then individually silenced each of the top 200 altered genes to see the effect on tumour growth.
They found 31 genes were important to growth of the cancer or its ability to survive, and from this group they determined NPTX2 was a key gene to cancer viability.
The study was published in the journal Cancer Research.